Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease.

Perco P, Ju W, Kerschbaum J, Leierer J, Menon R, Zhu C, Kretzler M, Mayer G, Rudnicki M; Nephrotic Syndrome Study Network (NEPTUNE).

JCI Insight. 2019 Jun 20;4(12). pii: 128120. doi: 10.1172/jci.insight.128120. eCollection 2019 Jun 20.

2.

The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17.

PMID:
31209404
3.

Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes.

Looker HC, Mauer M, Saulnier PJ, Harder JL, Nair V, Boustany-Kari CM, Guarnieri P, Hill J, Esplin CA, Kretzler M, Nelson RG, Najafian B.

J Am Soc Nephrol. 2019 Jun;30(6):1049-1059. doi: 10.1681/ASN.2018111166.

PMID:
31152118
4.

MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease.

Taroni JN, Grayson PC, Hu Q, Eddy S, Kretzler M, Merkel PA, Greene CS.

Cell Syst. 2019 May 22;8(5):380-394.e4. doi: 10.1016/j.cels.2019.04.003.

5.

A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.

Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS.

Nat Med. 2019 May;25(5):805-813. doi: 10.1038/s41591-019-0415-5. Epub 2019 Apr 22.

PMID:
31011203
6.

Low levels of urinary epidermal growth factor predict chronic kidney disease progression in children.

Azukaitis K, Ju W, Kirchner M, Nair V, Smith M, Fang Z, Thurn-Valsassina D, Bayazit A, Niemirska A, Canpolat N, Bulut IK, Yalcinkaya F, Paripovic D, Harambat J, Cakar N, Alpay H, Lugani F, Mencarelli F, Civilibal M, Erdogan H, Gellermann J, Vidal E, Tabel Y, Gimpel C, Ertan P, Yavascan O, Melk A, Querfeld U, Wühl E, Kretzler M, Schaefer F; 4C Study; ESCAPE Trial Group.

Kidney Int. 2019 Jul;96(1):214-221. doi: 10.1016/j.kint.2019.01.035. Epub 2019 Mar 20.

PMID:
31005273
7.

Health-related quality of life in glomerular disease.

Canetta PA, Troost JP, Mahoney S, Kogon AJ, Carlozzi N, Bartosh SM, Cai Y, Davis TK, Fernandez H, Fornoni A, Gbadegesin RA, Herreshoff E, Mahan JD, Nachman PH, Selewski DT, Sethna CB, Srivastava T, Tuttle KR, Wang CS, Falk RJ, Gharavi AG, Gillespie BW, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Guay-Woodford LM, Reeve B, Gipson DS; CureGN Consortium.

Kidney Int. 2019 May;95(5):1209-1224. doi: 10.1016/j.kint.2018.12.018. Epub 2019 Feb 27.

PMID:
30898342
8.

LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-β-Induced Angiogenesis.

Hong Q, Zhang L, Fu J, Verghese DA, Chauhan K, Nadkarni GN, Li Z, Ju W, Kretzler M, Cai GY, Chen XM, D'Agati VD, Coca SG, Schlondorff D, He JC, Lee K.

J Am Soc Nephrol. 2019 Apr;30(4):546-562. doi: 10.1681/ASN.2018060599. Epub 2019 Mar 11.

PMID:
30858225
9.

Glomerular podocytes in kidney health and disease.

Assady S, Benzing T, Kretzler M, Skorecki KL.

Lancet. 2019 Mar 2;393(10174):856-858. doi: 10.1016/S0140-6736(18)33000-9. No abstract available.

PMID:
30837131
10.

Upregulation of Tumor Susceptibility Gene 101 (TSG101) by mechanical stress in podocytes.

Sunohara M, Kriz W, Kränzlin B, Kretzler M, Gretz N, Endlich K, Endlich N.

Cell Mol Biol (Noisy-le-grand). 2019 Jan 31;65(1):84-88.

PMID:
30782301
11.

Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.

Dieter BP, Meek RL, Anderberg RJ, Cooney SK, Bergin JL, Zhang H, Nair V, Kretzler M, Brosius FC, Tuttle KR.

PLoS One. 2019 Feb 14;14(2):e0211555. doi: 10.1371/journal.pone.0211555. eCollection 2019.

12.

Correlation Between Baseline GFR and Subsequent Change in GFR in Norwegian Adults Without Diabetes and in Pima Indians.

Melsom T, Nair V, Schei J, Mariani L, Stefansson VTN, Harder JL, Jenssen TG, Solbu MD, Norvik JV, Looker H, Knowler WC, Kretzler M, Nelson RG, Eriksen BO.

Am J Kidney Dis. 2019 Jun;73(6):777-785. doi: 10.1053/j.ajkd.2018.11.011. Epub 2019 Jan 28.

PMID:
30704883
13.

Organoid single cell profiling identifies a transcriptional signature of glomerular disease.

Harder JL, Menon R, Otto EA, Zhou J, Eddy S, Wys NL, O'Connor C, Luo J, Nair V, Cebrian C, Spence JR, Bitzer M, Troyanskaya OG, Hodgin JB, Wiggins RC, Freedman BS, Kretzler M; European Renal cDNA Bank (ERCB); Nephrotic Syndrome Study Network (NEPTUNE).

JCI Insight. 2019 Jan 10;4(1). pii: 122697. doi: 10.1172/jci.insight.122697. [Epub ahead of print]

14.

Decoding the genetic determinants of gene regulation in the kidney.

Nair V, Kretzler M.

Kidney Int. 2019 Jan;95(1):16-18. doi: 10.1016/j.kint.2018.11.013. No abstract available.

PMID:
30606414
15.

Soluble ST2 and Galectin-3 and Progression of CKD.

Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, Gadegbeku CA, Gipson DS, Hawkins JJ, Himmelfarb J, Kestenbaum BR, Kretzler M, Robinson-Cohen C, Steigerwalt SP, Tuegel C, Bansal N.

Kidney Int Rep. 2018 Sep 21;4(1):103-111. doi: 10.1016/j.ekir.2018.09.013. eCollection 2019 Jan.

16.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

17.

Consent for Genetic Biobanking in a Diverse Multisite CKD Cohort.

Troost JP, Hawkins J, Jenkins DR, Gipson DS, Kretzler M, El Shamy O, Bellovich K, Perumal K, Bhat Z, Massengill S, Steigerwalt S, Pennathur S, Brosius FC, Gadegbeku CA; Michigan O’Brien Kidney Translational Research Center.

Kidney Int Rep. 2018 Jun 12;3(6):1267-1275. doi: 10.1016/j.ekir.2018.06.002. eCollection 2018 Nov.

18.

Tyro3 is a podocyte protective factor in glomerular disease.

Zhong F, Chen Z, Zhang L, Xie Y, Nair V, Ju W, Kretzler M, Nelson RG, Li Z, Chen H, Wang Y, Zhang A, Lee K, Liu Z, He JC.

JCI Insight. 2018 Nov 15;3(22). pii: 123482. doi: 10.1172/jci.insight.123482.

19.

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.

Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM; CureGN Consortium.

Am J Kidney Dis. 2019 Feb;73(2):218-229. doi: 10.1053/j.ajkd.2018.07.020. Epub 2018 Nov 9.

PMID:
30420158
20.

Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.

Mitrofanova A, Molina J, Varona Santos J, Guzman J, Morales XA, Ducasa GM, Bryn J, Sloan A, Volosenco I, Kim JJ, Ge M, Mallela SK, Kretzler M, Eddy S, Martini S, Wahl P, Pastori S, Mendez AJ, Burke GW, Merscher S, Fornoni A.

Kidney Int. 2018 Dec;94(6):1151-1159. doi: 10.1016/j.kint.2018.06.031. Epub 2018 Oct 6.

PMID:
30301568
21.

An integrative systems biology approach for precision medicine in diabetic kidney disease.

Mulder S, Hamidi H, Kretzler M, Ju W.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:6-13. doi: 10.1111/dom.13416. Review.

PMID:
30294956
22.

a-f BLAST: Non-Iterative Radial k-t BLAST Reconstruction for Real-Time Imaging.

Kretzler M, Hamilton J, Griswold M, Seiberlich N.

IEEE Trans Med Imaging. 2019 Mar;38(3):775-790. doi: 10.1109/TMI.2018.2872419. Epub 2018 Sep 27.

PMID:
30273146
23.

Single-cell analysis of progenitor cell dynamics and lineage specification in the human fetal kidney.

Menon R, Otto EA, Kokoruda A, Zhou J, Zhang Z, Yoon E, Chen YC, Troyanskaya O, Spence JR, Kretzler M, Cebrián C.

Development. 2018 Aug 30;145(16). pii: dev164038. doi: 10.1242/dev.164038.

24.

JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis.

Tao J, Mariani L, Eddy S, Maecker H, Kambham N, Mehta K, Hartman J, Wang W, Kretzler M, Lafayette RA.

Kidney Int. 2018 Oct;94(4):795-808. doi: 10.1016/j.kint.2018.05.022. Epub 2018 Aug 6.

PMID:
30093081
25.

Systems biology approaches to identify disease mechanisms and facilitate targeted therapy in the management of glomerular disease.

Hamidi H, Kretzler M.

Curr Opin Nephrol Hypertens. 2018 Nov;27(6):433-439. doi: 10.1097/MNH.0000000000000446. Review.

26.

An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome.

Gillies CE, Putler R, Menon R, Otto E, Yasutake K, Nair V, Hoover P, Lieb D, Li S, Eddy S, Fermin D, McNulty MT; Nephrotic Syndrome Study Network (NEPTUNE), Hacohen N, Kiryluk K, Kretzler M, Wen X, Sampson MG.

Am J Hum Genet. 2018 Aug 2;103(2):232-244. doi: 10.1016/j.ajhg.2018.07.004. Epub 2018 Jul 26.

27.

Single-Cell Sequencing the Glomerulus, Unraveling the Molecular Programs of Glomerular Filtration, One Cell at a Time.

Kretzler M, Menon R.

J Am Soc Nephrol. 2018 Aug;29(8):2036-2038. doi: 10.1681/ASN.2018060626. Epub 2018 Jul 12. No abstract available.

PMID:
30002221
28.

Renal matrix Gla protein expression increases progressively with CKD and predicts renal outcome.

Miyata KN, Nast CC, Dai T, Dukkipati R, LaPage JA, Troost JP, Schurgers LJ, Kretzler M, Adler SG.

Exp Mol Pathol. 2018 Aug;105(1):120-129. doi: 10.1016/j.yexmp.2018.07.001. Epub 2018 Jul 6.

29.

Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes.

Heinzel A, Kammer M, Mayer G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, Gilmour P, Wilson JM, Duffin KL, Abdalla M, McCarthy MI, Heinze G, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium.

Diabetes Care. 2018 Sep;41(9):1947-1954. doi: 10.2337/dc18-0532. Epub 2018 Jul 6.

PMID:
29980527
30.

Urinary epidermal growth factor as a prognostic marker for the progression of Alport syndrome in children.

Li B, Zhang Y, Wang F, Nair V, Ding F, Xiao H, Yao Y, Kretzler M, Ju W, Ding J.

Pediatr Nephrol. 2018 Oct;33(10):1731-1739. doi: 10.1007/s00467-018-3988-1. Epub 2018 Jun 11.

31.

Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome.

Debiec H, Dossier C, Letouzé E, Gillies CE, Vivarelli M, Putler RK, Ars E, Jacqz-Aigrain E, Elie V, Colucci M, Debette S, Amouyel P, Elalaoui SC, Sefiani A, Dubois V, Simon T, Kretzler M, Ballarin J, Emma F, Sampson MG, Deschênes G, Ronco P.

J Am Soc Nephrol. 2018 Jul;29(7):2000-2013. doi: 10.1681/ASN.2017111185. Epub 2018 Jun 14.

32.

GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.

Tuegel C, Katz R, Alam M, Bhat Z, Bellovich K, de Boer I, Brosius F, Gadegbeku C, Gipson D, Hawkins J, Himmelfarb J, Ju W, Kestenbaum B, Kretzler M, Robinson-Cohen C, Steigerwalt S, Bansal N.

Am J Kidney Dis. 2018 Oct;72(4):519-528. doi: 10.1053/j.ajkd.2018.03.025. Epub 2018 Jun 14.

PMID:
29866459
33.

High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping.

Czerniecki SM, Cruz NM, Harder JL, Menon R, Annis J, Otto EA, Gulieva RE, Islas LV, Kim YK, Tran LM, Martins TJ, Pippin JW, Fu H, Kretzler M, Shankland SJ, Himmelfarb J, Moon RT, Paragas N, Freedman BS.

Cell Stem Cell. 2018 Jun 1;22(6):929-940.e4. doi: 10.1016/j.stem.2018.04.022. Epub 2018 May 17.

34.

Renal Pre-Competitive Consortium (RPC2): discovering therapeutic targets together.

Tomilo M, Ascani H, Mirel B, Magnone MC, Quinn CM, Karihaloo A, Duffin K, Patel UD, Kretzler M.

Drug Discov Today. 2018 Oct;23(10):1695-1699. doi: 10.1016/j.drudis.2018.05.021. Epub 2018 May 18. Review.

PMID:
29778696
35.

Metabolic pathways and immunometabolism in rare kidney diseases.

Grayson PC, Eddy S, Taroni JN, Lightfoot YL, Mariani L, Parikh H, Lindenmeyer MT, Ju W, Greene CS, Godfrey B, Cohen CD, Krischer J, Kretzler M, Merkel PA; Vasculitis Clinical Research Consortium, the European Renal cDNA Bank cohort, and the Nephrotic Syndrome Study Network.

Ann Rheum Dis. 2018 Aug;77(8):1226-1233. doi: 10.1136/annrheumdis-2017-212935. Epub 2018 May 3.

36.

Urinary epidermal growth factor predicts renal prognosis in antineutrophil cytoplasmic antibody-associated vasculitis.

Wu L, Li XQ, Goyal T, Eddy S, Kretzler M, Ju WJ, Chen M, Zhao MH.

Ann Rheum Dis. 2018 Sep;77(9):1339-1344. doi: 10.1136/annrheumdis-2017-212578. Epub 2018 May 3.

PMID:
29724728
37.

FAR2 is associated with kidney disease in mice and humans.

Backer G, Eddy S, Sheehan SM, Takemon Y, Reznichenko A, Savage HS, Kretzler M, Korstanje R.

Physiol Genomics. 2018 Aug 1;50(8):543-552. doi: 10.1152/physiolgenomics.00118.2017. Epub 2018 Apr 13.

PMID:
29652635
38.

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.

Nephrol Dial Transplant. 2018 Nov 1;33(11):1950-1959. doi: 10.1093/ndt/gfx377.

39.

Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model.

Sas KM, Lin J, Rajendiran TM, Soni T, Nair V, Hinder LM, Jagadish HV, Gardner TW, Abcouwer SF, Brosius FC 3rd, Feldman EL, Kretzler M, Michailidis G, Pennathur S.

J Lipid Res. 2018 Feb;59(2):173-183. doi: 10.1194/jlr.M077222. Epub 2017 Dec 13.

40.

ORAI channels are critical for receptor-mediated endocytosis of albumin.

Zeng B, Chen GL, Garcia-Vaz E, Bhandari S, Daskoulidou N, Berglund LM, Jiang H, Hallett T, Zhou LP, Huang L, Xu ZH, Nair V, Nelson RG, Ju W, Kretzler M, Atkin SL, Gomez MF, Xu SZ.

Nat Commun. 2017 Dec 4;8(1):1920. doi: 10.1038/s41467-017-02094-y.

41.

An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.

Troost JP, Trachtman H, Nachman PH, Kretzler M, Spino C, Komers R, Tuller S, Perumal K, Massengill SF, Kamil ES, Oh G, Selewski DT, Gipson P, Gipson DS.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):414-421. doi: 10.2215/CJN.04780517. Epub 2017 Nov 22.

42.

Novel avenues for drug discovery in diabetic kidney disease.

Breyer MD, Kretzler M.

Expert Opin Drug Discov. 2018 Jan;13(1):65-74. doi: 10.1080/17460441.2018.1398731. Epub 2017 Nov 16. Review.

PMID:
29145743
43.

Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients.

Hallan S, Afkarian M, Zelnick LR, Kestenbaum B, Sharma S, Saito R, Darshi M, Barding G, Raftery D, Ju W, Kretzler M, Sharma K, de Boer IH.

EBioMedicine. 2017 Dec;26:68-77. doi: 10.1016/j.ebiom.2017.10.027. Epub 2017 Oct 31.

44.

A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome.

Nair V, Komorowsky CV, Weil EJ, Yee B, Hodgin J, Harder JL, Godfrey B, Ju W, Boustany-Kari CM, Schwarz M, Lemley KV, Nelson PJ, Nelson RG, Kretzler M.

Kidney Int. 2018 Feb;93(2):439-449. doi: 10.1016/j.kint.2017.08.013. Epub 2017 Oct 18.

45.

Defining Renal Neoplastic Disease, One Cell at a Time: Mass Cytometry, a New Tool for the Study of Kidney Biology and Disease.

Nelson PJ, Kretzler M.

Am J Kidney Dis. 2017 Dec;70(6):758-761. doi: 10.1053/j.ajkd.2017.08.009. Epub 2017 Oct 12. No abstract available.

PMID:
29031857
46.

Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease.

Pena MJ, Stenvinkel P, Kretzler M, Adu D, Agarwal SK, Coresh J, Feldman HI, Fogo AB, Gansevoort RT, Harris DC, Jha V, Liu ZH, Luyckx VA, Massy ZA, Mehta R, Nelson RG, O'Donoghue DJ, Obrador GT, Roberts CJ, Sola L, Sumaili EK, Tatiyanupanwong S, Thomas B, Wiecek A, Parikh CR, Heerspink HJL.

Kidney Int Suppl (2011). 2017 Oct;7(2):107-113. doi: 10.1016/j.kisu.2017.07.005. Epub 2017 Sep 20. Review.

47.

Genetic and environmental risk factors for chronic kidney disease.

Obrador GT, Schultheiss UT, Kretzler M, Langham RG, Nangaku M, Pecoits-Filho R, Pollock C, Rossert J, Correa-Rotter R, Stenvinkel P, Walker R, Yang CW, Fox CS, Köttgen A.

Kidney Int Suppl (2011). 2017 Oct;7(2):88-106. doi: 10.1016/j.kisu.2017.07.004. Epub 2017 Sep 20. Review.

48.

Transcriptome-based network analysis reveals renal cell type-specific dysregulation of hypoxia-associated transcripts.

Shved N, Warsow G, Eichinger F, Hoogewijs D, Brandt S, Wild P, Kretzler M, Cohen CD, Lindenmeyer MT.

Sci Rep. 2017 Aug 17;7(1):8576. doi: 10.1038/s41598-017-08492-y.

49.

FSGS as an Adaptive Response to Growth-Induced Podocyte Stress.

Nishizono R, Kikuchi M, Wang SQ, Chowdhury M, Nair V, Hartman J, Fukuda A, Wickman L, Hodgin JB, Bitzer M, Naik A, Wiggins J, Kretzler M, Wiggins RC.

J Am Soc Nephrol. 2017 Oct;28(10):2931-2945. doi: 10.1681/ASN.2017020174. Epub 2017 Jul 18.

50.

Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.

Afshinnia F, Zeng L, Byun J, Gadegbeku CA, Magnone MC, Whatling C, Valastro B, Kretzler M, Pennathur S; Michigan Kidney Translational Core CPROBE Investigator Group.

Am J Nephrol. 2017;46(1):73-81. doi: 10.1159/000477766. Epub 2017 Jul 1.

Supplemental Content

Loading ...
Support Center